Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Teva Branded Pharmaceutical Products R&D, Inc. | INDUSTRY |
This study will investigate the effects of a contingency-based musical walking intervention program called Ambulosono on neural mechanisms in the brain. The investigators will investigate the long-term impact of Ambulosono on brain plasticity with functional MRI technique. Participants will undergo 3 months of Ambulosono training and their pre-training and post-training fMRI brain scans will be compared to understand the neural networks and brain mechanisms following this intervention. The investigators hypothesized that Ambulosono may induce functional compensatory reorganization of neural networks in the brain. This project will allow us to address the important potential confound of placebo influence and to aid in optimizing this intervention program. Additionally, the investigators are hoping to investigate the synergistic effects of rasagiline and exercise; the investigators' hypothesis is that there will be a positive synergistic effect, and that exercise will augment the effectiveness of rasagiline in treating Parkinson's symptoms.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MCW | Experimental | Music Contingent Walking (MCW) group: study-specific musical device that measures gait and plays music in a portable manner as the participant is walking is set at a threshold individually calculated per participant, and the music will stop playing when walking strides fall below this threshold. |
|
| NCMW | Experimental | Non-contingent Music Walking (NCMW) group: music on all the time regardless of the stride size. |
|
| NMW | Experimental | Non-music walking (NMW/silent) group: no music on at all regardless of step size. |
|
| MCW+rasagiline | Experimental | Music contingent walking with rasagiline group: same paradigm as the previous MCW, but with rasagiline prescribed as adjunct therapy. Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day |
|
| MMW+rasagiline | Experimental | Non-music (silent) walking with rasagiline group: same paradigm as the previous NMW, but with rasagiline prescribed as adjunct therapy. Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Azilect | Drug | Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in brain imaging signals (fMRI) | resting state data task-evoked data cortical thickness volume sizes of specified brain structures | one month and four months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in motor symptoms of PD | Motor Symptoms:
| baseline and one month and four months |
| Change from baseline in cognition of PD |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in mood |
| baseline and one month and four months |
| Changes in impact/quality of life | PDQ-39 Quality of Life Questionnaire |
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria for fMRI
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tammy Kang | Contact | 604 822 9722 | tammy.kang@ubc.ca |
| Name | Affiliation | Role |
|---|---|---|
| Martin J McKeown, MD | University of British Columbia | Principal Investigator |
| Silke Cresswell, MD | University of British Columbia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pacific Parkinson's Research Centre | Recruiting | Vancouver | British Columbia | V6P 2Z9 | Canada |
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C031967 | rasagiline |
| D015444 | Exercise |
| D009147 | Music Therapy |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Exercise | Behavioral | Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms. |
|
| Music | Other |
|
Cognition:
|
| baseline and one month and four months |
| baseline and one month and four months |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D026421 | Sensory Art Therapies |
| D000529 | Complementary Therapies |
| D013812 | Therapeutics |
| D012046 | Rehabilitation |
| D000359 | Aftercare |
| D003266 | Continuity of Patient Care |
| D005791 | Patient Care |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |